Orgenesis Corp - רווח נקי למניה אחת בשנים עשר החודשים האחרונים ORGS
Orgenesis Inc. is recognized as an authoritative innovator in biomedical automation, as evidenced by the relative YoY (ttm) EPS change with a current figure of -40.20, reflecting the metric's value today. The company is pursuing expansion in the med-IT sector through B2B implementation of digital systems. High utilization of mobile cell processing units provides a stable operational base for the business.
Orgenesis Corp - פילוחים אנליטיים ומדדי מפתח (ORGS)
Orgenesis Inc. leverages a flexible talent management approach to attract capital through its innovative R&D model in gene therapy. This indicator captures the trailing twelve-month (TTM) earnings per share (EPS) trend, smoothing out quarterly volatility. By analyzing the current state of annual EPS TTM growth, investors can determine the business's real yield. High values signal overbought conditions, while dips indicate potential entry points. This metric objectively reflects the fundamental stability of the biotech startup.
